Which is the best choice in treating chronic myeloid leukemia in chronic phase: the first or second generation of TKI?
-
-
关键词:
- 白血病,髓细胞,慢性 /
- 酪氨酸激酶抑制剂
-
Key words:
- chronic myeloid leukemia /
- tyrosine kinase inhibitor
-
-
[1] O'Brien SG,Guilot F,Larson RA,et al.Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia[J].N Engl J Med,2003,348:994-1004.
[2] Hochhaus A,O'Brien SG,Guilot F,et al.Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia[J].Leukemia,2009,23:1054-1061.
[3] Deininger M,O'Brien SG,Guilhot F,et al.International randomized study of interferon vs STI571(IRIS) 8-year follow up:sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib[J].ASH Annual Meeting Abstracts,2009,114:1126.
[4] Druker BJ.Circumventing resistance to kinase-inhibitor therapy[J].N Engl J Med,2006,354:2594-2596.
[5] Talpaz M,Shah NP,Kantarjian H,et al.Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias[J].N Engl J Med,2006,354:2531-2541.
[6] Shah NP,Kantarjian HM,Kim DW,et al.Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia[J].J Clin Oncol,2008,26:3204-3212.
[7] Shah NP,Guilhot F,Cortes JE,et al.Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia:follow-up of a phase 3 study[J].Blood,2014,123:2317-2324.
[8] Kantarjian H,Shah NP,Hochhaus A,et al.Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia[J].N Engl J Med,2010,362:2260-2270.
[9] O'Brien SG,Hedgley C,Adams S,et al.Spirit 2:an NCRI randomized study comparing dasatinib with imatinib in patients with newly diagnosed CML[J].Blood (ASH Annual Meeting Abstracts),2014,124:517.
[10] Weisberg E,Manley P,Mestan J,et al.AMN107(nilotinib):a novel and selective inhibitor of BCR-ABL[J].Br J Cancer,2006,94:1765-1769.
[11] Kantarjian H,Giles F,Wunderle L,et al.Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL[J].N Engl J Med,2006,354:2542-2551.
[12] Kantarjian HM,Giles F,Gatterman N,et al.Nilotinib (formerly AMN107),a highly selective BCR-ABL tyrosine kinase inhibitor,is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance[J].Blood,2007,110:3540-3546.
[13] Saglio G,Kim DW,Issaragrisil S,et al.Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia[J].N Engl J Med,2010,362:2251-2259.
[14] Larson RA,Hochhaus A,Hughes TP,et al.Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase:ENESTnd 3-year follow up[J].Leukemia,2012,26:2197-2203.
[15] Larson RA,Kim DW,Jootar S,et al.ENESTnd 5-year (y) update:long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM)[J].J Clin Oncol (Meeting Abstracts),2014,32:7073.
[16] Gleevec (imatinib) package insert.Novartis Pharmaceuticals Corp;East Hanover,NJ:2014.
[17] Cortes J,Saglio G,Baccarani M,et al.Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION,CA180-056)[J].Blood (ASH Annual Meeting Abstracts),2014,124:152.
[18] Sprycel (dasatinib) package insert.Bristol-Myers Squibb Co;Princeton,NJ:2014.
[19] Quintas-Cardama A,Kantarjian H,O'Brien S,et al.Pleural effusions in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure[J].J Clin Oncol,2007,25:3908-3914.
[20] Porkka K,Khoury HJ,Paquette RL,et al.Dasatinib 100 mg once daily minimized the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion[J].Cancer,2010,116:377-386.
[21] Sokal JE,Cox EB,Baccarani M,et al.Prognostic discrimination in "good-risk" chronic granulocytic leukemia[J].Blood,1984,63:789-799.
[22] Hasford J,Pfirrmann M,Hehlmann R,et al.A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa[J].J Natl Cancer Inst,1998,90:850-858.
[23] Mahon FX,Rea D,Guilhot J,et al.Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years:the prospective,multicenter Stop Imatinib (STIM) trial[J].Lancet Oncol,2010,11:1029-1035.
[24] Ross DM,Branford S,Seymour JF,et al.Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease:results from the TWISTER study[J].Blood,2013,122:515-522.
[25] Mahon F,Richter J,Guilhot JG,et al.Interim analysis of a pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia:The EURO-SKI study[J].Blood (ASH Annual Meeting Abstracts),2014,124:151.
[26] Rea D,Nicolini FE,Tulliez M,et al.Dasatinib or nilotinib discontinuation in chronic phase (CP)-chronic myeloid leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts:interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months-on behalf of the French CML group filmc[J].Blood (ASH Annual Meeting Abstracts),2014,124:811.
[27] Experts in Chronic Myeloid Leukemia.The price of drugs for chronic myeloid leukemia is a reflection of the unsustainable prices of cancer drugs:from the perspective of a large group of CML experts[J].Blood,2013,121:4439-4442.
[28] Marin D,Bazeos A,Mahon F,et al.Adherence is the critical factor for achieving molecular respones in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib[J].J Clin Oncol,2010,28:2381-2388.
-
计量
- 文章访问数: 110
- PDF下载数: 230
- 施引文献: 0
下载: